| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $559K-98.7% | $43.3M+36.7% | $31.6M+46.1% | $21.7M |
| Cost of sales | -$215K+98.2% | -$11.8M+8.2% | -$12.9M+4.4% | -$13.5M |
| Gross profit | $344K-98.9% | $31.4M+67.5% | $18.8M+129.2% | $8.2M |
| Research and development costs | -$67.8M+0.2% | -$67.9M-19.2% | -$56.9M-30.7% | -$43.5M |
| General and administrative expenses | -$22.3M+16.9% | -$26.9M-2.5% | -$26.2M-2.1% | -$25.7M |
| Restructuring charges | -$1.3M | $0 | — | — |
| Operating loss | -$91.1M-43.8% | -$63.3M+1.7% | -$64.4M-5.5% | -$61.0M |
| Foreign currency (loss)/gain, net | -$8.5M-1410.7% | $646K+124.5% | -$2.6M-304.1% | $1.3M |
| Other income, net | $3.5M-22.2% | $4.5M+148.0% | $1.8M+543.9% | $280K |
| Benefit from R&D credit | $7.5M-45.7% | $13.7M+15.0% | $11.9M+21.7% | $9.8M |
| Loss before income tax expense | -$88.6M-99.3% | -$44.5M+16.5% | -$53.3M-7.3% | -$49.6M |
| Income tax expense | -$11K+98.7% | -$845K+11.6% | -$956K-39.0% | -$688K |
| Net Loss | -$88.6M-95.6% | -$45.3M+16.4% | -$54.2M-7.7% | -$50.3M |
| Loss per share basic | -$0.63-90.9% | -$0.33+32.7% | -$0.49+5.8% | -$0.52 |
| Loss per share diluted | -$0.63-90.9% | -$0.33+32.7% | -$0.49+5.8% | -$0.52 |
| Weighted-average shares outstanding basic | 141.69B+2.1% | 138.75B+24.7% | 111.28B+15.2% | 96.58B |
| Weighted-average shares outstanding diluted | 141.69B+2.1% | 138.75B+24.7% | 111.28B+15.2% | 96.58B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.